VEGFA and diabetes mellitus: The STAT3 inhibitor (S3I-201) ameliorates RAS activation and reduces the local production of VEGF in podocytes and renal tubule epithelium, which are induced by elevated ACE levels in diabetes (Zheng et al., 2019).